drugset / Trial / NCT02901249

Cost- Effectiveness and Quality of Life Assessment in Major Depression Disorder

NCT02901249

Phase 4 Completed 68 enrolled Federal University of Rio Grande do Sul
NaSequentialOpen-labelTreatment

Summary

To evaluate the effectiveness of one algorithm for Major Depression Disorder (MDD) using medications available in the Brazilian Public Healthcare System (SUS), and assessment of the quality of life of these patients. A randomized pragmatic trial was conducted. An algorithm was developed for the treatment of episodes of unipolar depression episodes.

Timeline

Start
2010-05
Primary completion
2014-11
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Lithium Unknown 900 mg
Subject Lithium Unknown 1500 mg
Subject Nortriptyline Small molecule 100 mg
Subject Sertraline Small molecule 50 mg
Subject Sertraline Small molecule 200 mg